CMA alleges collusion allowed 1,800% hike in Aspen drug pricing

African drugmaker Aspen was able to increase its prices for fludrocortisone acetate tablets by 1,800% in the UK, as a result of collusion with two other firms, according to the UK’s Competition and Markets Authority (CMA).

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Biotechnology

CMA reveals antitrust investigation into Essential Pharma over bipolar drug

30 November 2020 The UK Competition and Markets Authority is investigating Essential Pharma over suspicions that the pharmaceutical company contravened competition law by proposing to withdraw the supply of Priadel, a lithium-based medication for bipolar disease.

Big Pharma

NHS to receive £8m from Aspen over anti-competitive practices

15 August 2019 Drugmaker Aspen has offered to pay the UK’s National Health System £8 million to resolve competition concerns.

Big Pharma

CMA accuses 4 pharma companies of anti-competitive conduct

24 May 2019 Four pharmaceutical companies allegedly agreed not to compete for the supply of an anti-nausea tablet to the National Health Service, according to objections filed by the UK Competition and Markets Authority.